2023 Rheumatology Year in Review

Save

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  

2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

2023 Rheumatology Year in Review

Save

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Heritability of Osteoarthritis

Save

A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.

New Year's Resolutions (1.5.2024)

Save

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Save

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Best of 2023: 25 Great Women in Rheumatology

Save

This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

RheumNow Podcast – Bill of Rights (12.15.2023)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery. 

Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA

Save

Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.

ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

Save

Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated. 

ICYMI: SpA Sleuths: The Case of Undiagnosed IBD

Save

Abstract #0494 provides context to our continual search for better understanding of inflammatory bowel disease in patients with AS, nr-AxSpA, and PsA.